We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Diagnostic Drug Decision Highlights Clinical Trial Challenges
CMS Diagnostic Drug Decision Highlights Clinical Trial Challenges
October 10, 2013
The Centers for Medicare & Medicaid Services’ decision to limit coverage of a diagnostic imaging drug for Alzheimer’s disease not only threatens the development of such drugs, but illustrates how industry must rethink clinical trial design, stakeholders say.